Literature DB >> 8529283

Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro.

J Klostergaard1, M E Leroux, H A Hsu, B P Hsi, Z H Siddik, L L Danhauser, S P Tomasovi.   

Abstract

Effective adjunctive therapies for colorectal carcinoma are clearly needed. We evaluated the cytotoxic responses in vitro of human colon carcinoma cell lines to combined modalities: 5-fluorouracil/leucovorin (5-FU/LV), carboplatin (CP), tumor necrosis factor (TNF) and hyperthermia (HTX). Cytotoxicity was evaluated in a cell proliferation assay using crystal violet staining. 5-FU/LV was administered 2-3 days before TNF and CP, followed 1 h later by HTX. These cell lines were relatively resistant to HTX alone (42 degrees C for 2 h), but were heterogeneous in their responses to various doses of the other single agents. This heterogeneity was also evident for combined modalities: the HCT-15 cell line exhibited significant supra-additivity for selected doses of CP, TNF and 5-FU/LV, which was further enhanced by hyperthermia. In contrast, the HT-29 cell line did not demonstrate a strong pattern for supra-additivity, whereas the DLD-1 cell line had an intermediate response. Thus, our results suggest one approach to develop effective and dose-sparing multimodality therapeutic regimens for colon adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8529283     DOI: 10.1007/bf00688322

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases.

Authors:  G M Mavligit; A A Zukiwski; C Charnsangavej; C H Carrasco; S Wallace; J U Gutterman
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

2.  The expected effect of a combination of agents: the general solution.

Authors:  M C Berenbaum
Journal:  J Theor Biol       Date:  1985-06-07       Impact factor: 2.691

Review 3.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

Authors:  M A Poon; M J O'Connell; C G Moertel; H S Wieand; S A Cullinan; L K Everson; J E Krook; J A Mailliard; J A Laurie; L K Tschetter
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

4.  Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma.

Authors:  M Schaadt; M Pfreundschuh; G Lorscheidt; K M Peters; T Steinmetz; V Diehl
Journal:  J Biol Response Mod       Date:  1990-04

5.  Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer.

Authors:  J E Cantrell; R D Hart; R F Taylor; J H Harvey
Journal:  Cancer Treat Rep       Date:  1987-06

6.  The effect of whole body hyperthermia on 5-fluorouracil pharmacokinetics in vivo and clonogenicity of mammalian colon cancer cells.

Authors:  J Lange; K S Zänker; J R Siewert; G Blümel; K Eisler; E Kolb
Journal:  Anticancer Res       Date:  1984 Jan-Apr       Impact factor: 2.480

7.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

8.  Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy.

Authors:  J Klostergaard; E Leroux; Z H Siddik; M Khodadadian; S P Tomasovic
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

9.  The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platin.

Authors:  S Palmeri; F Trave; O Russello; Y M Rustum
Journal:  Sel Cancer Ther       Date:  1989

10.  Cancer statistics, 1995.

Authors:  P A Wingo; T Tong; S Bolden
Journal:  CA Cancer J Clin       Date:  1995 Jan-Feb       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.